Background and Objective: The relationship between protoporphyrin IX (PpIX)
Introduction
Non-melanoma skin cancers (NMSC) and associated precancerous lesions originate from non-melanocytic cell types within the epidermis and they are the most common malignancy in the Caucasian population (1) . They comprise more than one-third of all adult cancers within the U.S. (approximately 900,000 to 1,200,000 cases per year) (2) and the incidence is steadily increasing worldwide at a rate of 3 % -8 % each year (3) . Although these cancers rarely metastasise, when left untreated they can cause extensive local damage to the skin and often disfigure the patient (due to their frequently prominent localisation in sun exposed areas). The treatment of NMSC and the associated precancerous lesions therefore places a huge burden on health organisations.
Photodynamic therapy (PDT) is a highly selective technique for the ablation of tumor
tissue via the production of singlet oxygen and other reactive oxygen species (ROS) (4) . The photodynamic reactions generate the ROS providing that three critical components are present; a photosensitiser, light of the appropriate wavelength and oxygen (5) . Topical PDT with the application of a prodrug (aminolevulinic acid, ALA or its methyl ester MAL) has found a niche in the treatment of dermatological conditions, especially in treating NMSC and other precancerous skin lesions (e.g. basal cell carcinoma (BCC), Bowen's disease (BD) and actinic keratosis (AK)) which are all licensed indications in the UK (6) . High complete response rates are observed when treating these lesions with topical PDT and these are comparable to the standard treatment modalities of cryosurgery and surgical excision (7) (8) (9) (10) . PDT has several advantages over standard treatment for NMSC and precancerous 5 lesions, particularly in terms of improved cosmetic outcome and the ability to easily treat large or multiple lesions (7) (8) (9) (10) .
Endogenous protoporphyrin IX (PpIX) accumulates within cells following the topical application of ALA/MAL, which are converted enzymatically via the heme biosynthesis pathway (11, 12) . PpIX accumulation occurs preferentially within tumor cells probably as a result of disruption of the stratum corneum and differences in enzyme activity within neoplastic and normal tissues (13) . The accumulated PpIX is activated via the application of red light (635 nm). The majority of this energy dissipates as heat or fluorescence but occasionally a high energy triplet state is formed (12) . Interaction of the triplet state PpIX with molecular oxygen results in the production of singlet oxygen and other reactive oxygen species (ROS) which cause localised oxidative damage to the cells resulting in cell death via apoptosis or necrosis (14) . The characteristic optical properties of PpIX enable fluorescence diagnosis (FD) a technique that identifies and demarcates tumors and pre-cancers due to their preferential accumulation of PpIX in comparison with normal skin, thereby aiding diagnosis and surgical excision (15-18). In addition FD equipment with appropriate validation/modification has the potential to follow the accumulation and destruction of the photosensitizer during real-time PDT.
This study employed a commercially available imaging system (Dyaderm, Biocam, Germany) to monitor the changes in PpIX during real-time clinical dermatological MAL-PDT. We have previously validated this system to ensure that changes in PpIX levels can be reproducibly followed during dermatological PDT (19) . Previous in vivo studies have indicated the positive correlation between PpIX photobleaching and cellular damage, indicating that greater photobleaching enhances the efficacy of the treatment (20) (21) (22) . This investigation considered the levels of PpIX photobleaching 6 and total PpIX fluorescence observed at the time of treatment with the clinical outcome at three months to determine whether this system had the potential to act as a predictor of treatment efficacy at the time of PDT treatment.
Materials and Methods

Fluorescence imaging
PpIX fluorescence was determined using a pre validated non-invasive imaging system (Dyaderm, Biocam, Germany) (19) . The system consisted of a Xenon flash light source that had a custom bandpass filter (370-440 nm) enabling alternation between white and blue light. The light source had a low irradiance (3-5 mWcm -2 ) and a short exposure time to minimise ROS production during light irradiation.
Previous investigations within our group have shown no significant alterations in PpIX fluorescence when sequential measurements were acquired (data not shown).
Seven light pulses per second were delivered to the area of interest, and the returning light was collected by a 12-bit Sony charge coupled device (CCD) camera (exposure time 100 µs) which utilised a special Schott GG 455 longpass filter to exclude the excitation light. The light source and CCD were combined in one adjustable arm coupled to a Pentium IV computer equipped with custom-made image capturing software (Dyaderm Pro v2, Biocam, Germany). The red pixels of the CCD camera (spectral sensitivity of which at 630 nm was between 85% and 90%) were used to generate a fluorescence image from the red spectrum fluorescence emitted from the excited PpIX. In this way, a normal coloured image (from the white light) and a fluorescence image (from the blue light 370-440 nm) was simultaneously collected and processed by the system in real time.
In addition to PpIX other fluorophores within the skin (e.g. lipopigments and flavins)
were activated with the blue light and emitted light in the green spectrum. This autofluorescence was also recorded by the camera. The software computed a "PpIX known as Metvix®, Galderma, UK). The lesion was then occluded from the light for a period of three hours. After the allotted time the lesion was irradiated with a red light (Aktilite, Galderma, UK; 635 nm +/-5 nm; 37 Jcm -2 ; 90 mWcm -2 ) which was positioned by a specialist nurse practitioner to be between 5 and 8 centimetres away from the lesion (in accordance with the NICE treatment guidelines (24)).
The lesions were imaged at multiple time points during standard PDT treatment, specifically prior to the application of MAL, after the three hour MAL application period and immediately following light irradiation. All images were taken in accordance with our previously derived standardised operating procedure which enabled reproducible images to be acquired by limiting the other factors potentially altering image acquisition (19) . To enable the identical region to be imaged the position of the camera was marked on the patients' skin to enable replacement of the camera in the same place. The fluorescence intensity within images (arbitrary units (AU)) were then analyzed at a consistent pixel position using ImageJ software to follow the changes in PpIX fluorescence within the lesion at the different points in the treatment. When patients attended the clinic for a second treatment nine days later the images were acquired and analyzed in exactly the same manner.
Outcome at three months
All patients attended an outpatient clinic three months after their last PDT treatment and the lesions were visually assessed by a Consultant Dermatologist who was blinded to the fluorescence imaging results. The outcome reported was based on the initial assessment of the lesion entered in the notes, which included details of the lesion size and an image of the lesion prior to treatment. If no clinical evidence of the tumour remained at three months then the lesions were considered to have undergone complete clinical clearance. Lesions that were observed to have decreased in size but where (pre)cancerous cells clearly remained were reported to have undergone a partial clearance. Lesions which remained unaltered following the one or two PDT treatments they had received were reported as no clearance.
Data analysis
The clinical outcomes recorded were related to the image analysis data in particular the total PpIX fluorescence recorded after the three hour MAL application and the percentage change in fluorescence intensity observed during light irradiation. For each patient the total fluorescence after the three hour application of MAL was noted and the percentage change in fluorescence during light irradiation was calculated.
The values were then allotted to the appropriate group (i.e. complete, partial or no clearance) and the median values of the outcome group calculated. The analysis looked initially at the first and second MAL-PDT treatments separately and then the data were combined.
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These non-parametric data were analysed using the Mann Whitney U test to compare the percentage changes in fluorescence during light irradiation or total PpIX fluorescence after the three hour MAL application observed in lesions undergoing complete, partial and no clearance. Due to the low number of patients undergoing no clearance statistical analysis was only conducted between the complete and partial clearance groups.
The z-test for two proportions was utilized to compare the percentage of patients within the complete and partial clearance groups that underwent a greater than 40%, 50% and 60% fluorescence change in PpIX.
It should be noted that this non-interventional, non-randomised, observational study of routine dermatological MAL-PDT practice was not powered in advance as no idea of the size of change in fluorescence intensity that might be observed during clinical light irradiation was previously known or indeed how this may be related (if at all) to the clinical outcome observed at three months.
Results
Total PpIX fluorescence
The median total PpIX fluorescence observed after the three hour MAL application were similar in all patients independent of the clinical outcome observed at three months (1 st treatment: complete 132.94 au, partial 126.36 au and no response 108.57 au; 2 nd treatment: complete 104.91 au, partial 100.48 au and no response 150 au) (Figure 1 ). When the grayscale fluorescence intensities after MAL application for complete responders (n = 72) were compared to the grayscale intensities for partial responders (n = 27) no significant differences were observed in lesions undergoing the first PDT treatment alone (P=0.529), nor the second PDT treatment alone (P=0.641), nor when the combination of the first and second treatments were analysed together (P=0.598) (Figure 1 ).
Percentage change in fluorescence intensity during light irradiation
Light irradiation resulted in a statistically significant decrease in the fluorescence intensity within the lesions which corresponded to the photobleaching of the lesion.
Patients observed to undergo complete clinical clearance (n = 72) had statistically higher levels of change in PpIX fluorescence intensity during the first and second PDT treatments (P<0.005) in comparison to those patients who only underwent partial clearance (n = 27) (Figure 2 ).
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Determination of an optimal percentage change in fluorescence
The percentage of lesions undergoing a change in fluorescence intensity of greater than 40% during light irradiation was not noted to differ significantly between complete and partial responders. In contrast fluorescence changes of 50% and 60%
were significantly more likely within the complete responders group when compared with the partial responders group (P<0.01 and P<0.001 respectively, 90% power; Figure 3 ). When a 70% change was analysed, the number of patients undergoing such a considerable change was considered too low for this to be a useful threshold.
Discussion
MAL-PDT has become a successful treatment modality for the treatment of NMSC and skin pre-cancers (6, 7, 25) . The endogenous photosensitizer, PpIX, produced from the topical precursor MAL accumulates specifically within these lesions (12, 13, 26) and results in the production of singlet oxygen and other ROS when activated with red light. Previous studies have shown a positive correlation between PpIX photobleaching and the induced cellular damage, indicating that greater PpIX photobleaching results in more efficacious PDT (20) (21) (22) 27) . Therefore the potential exists to follow PpIX photobleaching and utilize it as a predictive tool in determining clinical outcome within the clinical setting.
The characteristic fluorescent properties of PpIX enables fluorescence imaging which is normally employed to identify and demarcate lesions to aid their removal, but it also has the potential to follow PpIX accumulation and destruction during PDT (16) . Fluorescence spectroscopy is commonly used to follow changes in PpIX in vitro (28, 29) and in animal models (22, 30, 31) , however to date limited clinical data is available due to the poor reproducibility of results (32) . This study utilised a system which we had previously validated to follow PpIX changes during MAL-PDT (19) and related these to the observed clinical outcome after three months. Monitoring PpIX photobleaching in vivo is known to be technically feasible (22, 30, 31, 35) and has been demonstrated in this present work for the first time in patients undergoing dermatological MAL-PDT. Despite this, the mechanistic relationships between photobleaching and the resulting photo-damage are not trivial (36) . The rate of photobleaching is thought to be dependent on the light fluence, photosensitiser concentration and the partial pressure of oxygen (pO2) within the tissues under investigation (36) . In terms of this study the light fluence was constant and therefore fluence and fluence rate were not a variable. In contrast the pO2 will be of critical importance to the efficacy of PDT as it is related to the level of singlet oxygen produced within the localised area (37) . The oxygenation of the tissue is known to determine the photobleaching rate (36) and therefore the initial value of pO2 within the tissue needs to be considered. During light delivery the oxygen level will be reduced due to photochemical consumption, and due to the variability in initial tissue pO2, in some instances photobleaching may switch from oxygen-dependent to oxygen-independent mechanisms (38) . A link between oxygen-independent photobleaching and photochemical damage is yet to be determined however. This indicates that photobleaching alone may not be suitable to determine clinical outcome in patients undergoing MAL-PDT as the fluorescence measurements alone do not consider oxygen independent photobleaching, which due to the heterogeneity of microvasculature in skin is certainly plausible. Although in the skin a proportion of the oxygenation comes from the atmosphere rather than the vasculature (39).
Previous literature has indicated that PpIX photobleaching differs at various PpIX concentrations in vitro, with higher PpIX concentrations relating to lower PpIX photobleaching (20, 40) . This is proposed to occur due to the localisation of PpIX at secondary sites (which protect PpIX from singlet oxygen or make it less photoactive) following the saturation of the primary binding sites. The clinical relevance of this is currently not known, and in this study with the sample size investigated no significant difference was observed in the total PpIX fluorescence observed prior to light irradiation in the complete and partial responders (P>0.500).
The clinical data presented here are consistent with the literature in terms of the positive correlation previously observed between PpIX photobleaching and cellular damage (20) (21) (22) 41) . Importantly this study looks at percentage change in fluorescence rather than the raw data generated from the non-invasive imaging system utilized which would be device specific and therefore the thresholds postulated here with investigation could be utilized by other clinical investigators with other fluorescence monitoring devices.
This study has indicated the potential of a commercially available fluorescence imaging system to follow changes in PpIX fluorescence non-invasively in real time during routine dermatological practice and also indicates that it may be possible to use PpIX photobleaching during light irradiation to give an indication of likely treatment outcome at three month follow-up whilst PDT is still in progress.
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